123 related articles for article (PubMed ID: 35382974)
1. Angiopoietin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension.
Bauer D; Kozbial K; Schwabl P; Chromy D; Simbrunner B; Stättermayer AF; Pinter M; Steindl-Munda P; Trauner M; Ferenci P; Reiberger T; Mandorfer M
Dig Liver Dis; 2022 Sep; 54(9):1222-1229. PubMed ID: 35382974
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive tests for clinically significant portal hypertension after HCV cure.
Semmler G; Lens S; Meyer EL; Baiges A; Alvardo-Tapias E; Llop E; Tellez L; Schwabl P; Mauro E; Escudé L; Díez C; Ibañez-Samaniego L; Puente Á; Fortea JI; Abadía M; Zanetto A; Conthe A; Hernandez-Évole H; Luzko Scheid IS; Jia J; Yoshiji H; Francque SM; Tsochatzis EA; Russo FP; Crespo G; Forns X; Bañares R; Villanueva C; Hernández-Gea V; Reiberger T; Bosch J; García Pagán JC; Mandorfer M;
J Hepatol; 2022 Dec; 77(6):1573-1585. PubMed ID: 36063968
[TBL] [Abstract][Full Text] [Related]
3. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.
Mandorfer M; Kozbial K; Schwabl P; Freissmuth C; Schwarzer R; Stern R; Chromy D; Stättermayer AF; Reiberger T; Beinhardt S; Sieghart W; Trauner M; Hofer H; Ferlitsch A; Ferenci P; Peck-Radosavljevic M
J Hepatol; 2016 Oct; 65(4):692-699. PubMed ID: 27242316
[TBL] [Abstract][Full Text] [Related]
4. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy.
Mandorfer M; Kozbial K; Schwabl P; Chromy D; Semmler G; Stättermayer AF; Pinter M; Hernández-Gea V; Fritzer-Szekeres M; Steindl-Munda P; Trauner M; Peck-Radosavljevic M; García-Pagán JC; Ferenci P; Reiberger T
Hepatology; 2020 Mar; 71(3):1023-1036. PubMed ID: 31365764
[TBL] [Abstract][Full Text] [Related]
5. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease.
Schwabl P; Mandorfer M; Steiner S; Scheiner B; Chromy D; Herac M; Bucsics T; Hayden H; Grabmeier-Pfistershammer K; Ferlitsch A; Oberhuber G; Trauner M; Peck-Radosavljevic M; Reiberger T
Aliment Pharmacol Ther; 2017 Jan; 45(1):139-149. PubMed ID: 27910154
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
[TBL] [Abstract][Full Text] [Related]
7. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive candidate protein signature predicts hepatic venous pressure gradient reduction in cirrhotic patients after sustained virologic response.
Richards SM; Guo F; Zou H; Nigsch F; Baiges A; Pachori A; Zhang Y; Lens S; Pitts R; Finkel N; Loureiro J; Mongeon D; Ma S; Watkins M; Polus F; Albillos A; Tellez L; Martinez-González J; Bañares R; Turon F; Ferrusquía-Acosta J; Perez-Campuzano V; Magaz M; Forns X; Badman M; Sailer AW; Ukomadu C; Hernández-Gea V; Garcia-Pagán JC
Liver Int; 2023 Sep; 43(9):1984-1994. PubMed ID: 37443448
[TBL] [Abstract][Full Text] [Related]
9. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
Afdhal N; Everson GT; Calleja JL; McCaughan GW; Bosch J; Brainard DM; McHutchison JG; De-Oertel S; An D; Charlton M; Reddy KR; Asselah T; Gane E; Curry MP; Forns X
J Viral Hepat; 2017 Oct; 24(10):823-831. PubMed ID: 28295923
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease.
Pomej K; Scheiner B; Balcar L; Nussbaumer RJ; Weinzierl J; Paternostro R; Simbrunner B; Bauer D; Pereyra D; Starlinger P; Stättermayer AF; Pinter M; Trauner M; Quehenberger P; Reiberger T; Mandorfer M
Dig Liver Dis; 2022 Oct; 54(10):1376-1384. PubMed ID: 35871985
[TBL] [Abstract][Full Text] [Related]
11. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C.
Mauro E; Crespo G; Montironi C; Londoño MC; Hernández-Gea V; Ruiz P; Sastre L; Lombardo J; Mariño Z; Díaz A; Colmenero J; Rimola A; Garcia-Pagán JC; Brunet M; Forns X; Navasa M
Hepatology; 2018 May; 67(5):1683-1694. PubMed ID: 28960366
[TBL] [Abstract][Full Text] [Related]
12. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
[TBL] [Abstract][Full Text] [Related]
13. Adipopenia correlates with higher portal pressure in patients with cirrhosis.
Rodrigues SG; Brabandt B; Stirnimann G; Maurer MH; Berzigotti A
Liver Int; 2019 Sep; 39(9):1672-1681. PubMed ID: 31207018
[TBL] [Abstract][Full Text] [Related]
14. Use of transient elastography (FibroScan®) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients.
Sánchez-Conde M; Miralles P; Bellón JM; Rincón D; Ramírez M; Gutiérrez I; Ripoll C; López JC; Cosín J; Clemente G; Lo Iacono O; Bañares R; Berenguer J
J Viral Hepat; 2011 Oct; 18(10):685-91. PubMed ID: 21914085
[TBL] [Abstract][Full Text] [Related]
15. Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death.
Jachs M; Hartl L; Simbrunner B; Bauer D; Paternostro R; Scheiner B; Schwabl P; Stättermayer AF; Pinter M; Eigenbauer E; Quehenberger P; Trauner M; Reiberger T; Mandorfer M
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1362-1373.e6. PubMed ID: 34256145
[TBL] [Abstract][Full Text] [Related]
16. PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertension.
Jansen C; Leeming DJ; Mandorfer M; Byrjalsen I; Schierwagen R; Schwabl P; Karsdal MA; Anadol E; Strassburg CP; Rockstroh J; Peck-Radosavljevic M; Møller S; Bendtsen F; Krag A; Reiberger T; Trebicka J
PLoS One; 2014; 9(9):e108544. PubMed ID: 25265505
[TBL] [Abstract][Full Text] [Related]
17. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
La Mura V; Reverter JC; Flores-Arroyo A; Raffa S; Reverter E; Seijo S; Abraldes JG; Bosch J; García-Pagán JC
Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis.
Kirnake V; Arora A; Sharma P; Goyal M; Chawlani R; Toshniwal J; Kumar A
Indian J Gastroenterol; 2018 Jul; 37(4):335-341. PubMed ID: 30178093
[TBL] [Abstract][Full Text] [Related]
19. Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease.
Simbrunner B; Stadlmann A; Schwabl P; Paternostro R; Bauer DJM; Bucsics T; Scheiner B; Lampichler K; Wöran K; Beer A; Eigenbauer E; Pinter M; Stättermayer AF; Marculescu R; Szekeres T; Trauner M; Mandorfer M; Reiberger T
Dig Liver Dis; 2021 Mar; 53(3):345-352. PubMed ID: 33032973
[TBL] [Abstract][Full Text] [Related]
20. Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy.
Puente Á; Cabezas J; López Arias MJ; Fortea JI; Arias MT; Estébanez Á; Casafont F; Fábrega E; Crespo J
Rev Esp Enferm Dig; 2017 Jan; 109(1):17-25. PubMed ID: 27990835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
